GENESIS Biomed has acted in some cases as Venture Builder. The spin-off Telara Pharma and the spin-off RetinaReadRisk are two successful examples where GENESIS Biomed has played this role.
Read moreAunque la cirugía de cataratas es una de las intervenciones más realizadas a nivel mundial, con aproximadamente 30 millones de operaciones anuales, todavía existe mucho desconocimiento sobre la int...
Read moreSparingVision today announces a key advancement in its Phase I/II clinical trial for SPVN06, the Company’s lead gene-agnostic investigational gene therapy for the treatment of retinitis pigmentosa (...
Read moreResearchers at the University of Barcelona are participating in a new consortium to design a drug with an innovative approach against this disease, which could also be used to treat other hereditary r...
Read moreHan comprobado que este biomaterial inyectable, diseñado mediante bioingeniería, puede sellar y rellenar perforaciones en córneas inflamadas y promover su regeneración, evitando así la necesidad ...
Read moreA paper published in the journal Cells has identified a potential modifier gene for PCD by studying a family in which the mother and two sons are affected by X-linked retinitis pigmentosa (XLRP), and ...
Read moreThe results showed that the retinal layer is noticeably thinner in Parkinson's patients. During the initial phases of the disease it is in the retina where the greatest neurodegeneration is detected, ...
Read more